Answer
Yes, tumour lysis syndrome, which may be life-threatening or fatal, has been reported in patients receiving inotuzumab ozogamicin.
Sources for this answer
- BESPONSA 1 mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 12Document updated
Sources checked